Ubals Maria, Bosch-Nicolau Pau, Sánchez-Montalvá Adrián, Salvador Fernando, Aparicio-Español Gloria, Sulleiro Elena, Silgado Aroa, Soriano-Arandes Antoni, Espiau Maria, Ferrer Berta, Pou Diana, Treviño Begoña, Molina Israel, García-Patos Vicente
Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Doctoral Programme in Medicine and Translational Research: International Health Track, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain.
Pathogens. 2021 Sep 28;10(10):1253. doi: 10.3390/pathogens10101253.
There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome.
We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included.
The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment.
L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
对于复杂性皮肤利什曼病（CL）的最佳治疗方法尚无共识。我们旨在描述一组CL病例，重点关注脂质体两性霉素B（L-AmB）的治疗结果。
我们在巴塞罗那的瓦尔德希伯伦大学医院进行了一项回顾性研究。纳入了所有在2012年至2018年期间经寄生虫学确诊为CL的患者。
分析包括41例CL患者。中位年龄为39岁（四分位间距12 - 66岁）；12例（29%）为儿童，29例（71%）为男性。关于治疗，24例（59%）接受了局部治疗，而17例（41%）患有复杂性CL并接受了静脉全身治疗。16例患者接受了L-AmB治疗；8例（50%）出现不良事件，3例（19%）因安全原因停止治疗。所有病例在治疗后的第一年内均被视为治愈。
L-AmB治疗复杂性CL未出现治疗失败情况，为复杂性CL患者提供了一种替代治疗选择。临床医生应密切关注L-AmB的潜在不良事件，并采用积极的药物安全监测方案以快速发现可逆性副作用。
